NAFLD
Non-alcoholic fatty liver disease (NAFLD) is recognized as a common liver disease in many countries and comprises a spectrum of diseases, ranging from simple steatosis of the liver to fibrosis and cirrhosis. The prevalence of this disorder in general population is reported to be 20–30%. A body of evidence suggests that NAFLD is correlated to compositional changes in the intestinal microflora and altered intestinal permeability. Gut microbiota modulation by probiotics could represent a promising therapeutic strategy for this disease and related conditions.
300 g of yogurt per day
This study provides evidence of possible beneficial effects of probiotic products in non-alcoholic fatty liver disease (NAFLD). This randomized double-blind controlled clinical trial, was made to 72 NAFLD patients who where divided in two groups. During 8 week one group consumed 300 g/day of probiotic yogurt containing Lactobacillus acidophilus La5 and Bifidobacteriumlactis Bb12. The other group consumed 300 g/day of conventional yogurt.
Probiotics reduce fatty liver disease
Researchers found that patients from the probiotic yogurt had a significant reduction in weight, body mass index, and serum levels of fasting insulin as compared with that in the control group. No significant changes were observed in other parameters in both groups. Further studies are warranted to investigate the possible effects of probiotic products on these adipokines in NAFLD patients.
